Tiagabine Shortage: What Providers and Prescribers Need to Know in 2026

Tiagabine (Gabitril), a selective GABA reuptake inhibitor (GAT-1 inhibitor) approved as adjunctive therapy for partial seizures in patients 12 years and older, is not currently listed on the FDA's drug shortage database. However, prescribers are increasingly hearing from patients who struggle to locate tiagabine at their local pharmacy. This clinical overview addresses the availability landscape, patient safety implications, and practical guidance for managing affected patients.

Current Availability Status

As of 2026, tiagabine is not in an FDA-declared shortage. Generic tiagabine is manufactured by multiple suppliers and is available through major pharmaceutical wholesalers (McKesson, AmerisourceBergen, Cardinal Health). The challenge is a distribution and stocking issue, not a manufacturing deficit.

Because tiagabine has a narrow therapeutic niche — adjunctive therapy for partial seizures when first-line AEDs are inadequate — prescriptions are relatively infrequent at most retail pharmacies. Many pharmacies, particularly smaller chains and rural independents, do not routinely stock it. This creates patient-level availability gaps even when manufacturer supply is intact.

Patient Safety Considerations

Unlike many medications where brief supply interruptions cause inconvenience, disruptions in tiagabine therapy carry significant clinical risk. Prescribers should counsel patients — and document this counseling — about the following:

Abrupt discontinuation risk: Sudden cessation of tiagabine is associated with increased seizure frequency and risk of status epilepticus. The FDA labeling states: "As a rule, antiepileptic drugs should not be abruptly discontinued because of the possibility of increasing seizure frequency."

Driving and occupational hazards: A breakthrough seizure triggered by missed tiagabine doses may disqualify a patient from driving in their state. Patients should be aware that even a brief lapse in medication can have lasting practical consequences.

Dose-dependent pharmacokinetics: Tiagabine clearance is significantly affected by concomitant enzyme-inducing AEDs. Patients on carbamazepine, phenytoin, phenobarbital, or primidone have tiagabine plasma levels 50-75% lower than non-induced patients. Any interruption in therapy must account for this pharmacokinetic context when re-initiating treatment.

Clinical Management Recommendations

For patients currently stable on tiagabine who report pharmacy difficulty, consider the following proactive measures:

Route prescriptions to mail-order pharmacies. Mail-order pharmacies (through the patient's insurance PBM) maintain larger inventories of niche medications and can provide 90-day supplies, significantly reducing refill frequency and stocking issues.

Identify reliable local pharmacies. When possible, establish relationships with local pharmacies (or specialty neurological pharmacies) that routinely stock tiagabine. Some hospital-affiliated outpatient pharmacies are more reliable sources for specialty AEDs.

Prescribe 90-day supplies. Where clinically appropriate and permitted by insurance, write for 90-day supplies to reduce the frequency of potential supply disruptions.

Document refill planning in patient records. Note the pharmacy, last fill date, and supply duration in the chart to support continuity across care team members.

Therapeutic Alternatives When Tiagabine Is Unavailable

If a patient faces an imminent supply disruption and transition is clinically necessary, consider the following adjunctive AED options for partial seizures:

Lamotrigine (Lamictal): Widely available generic; requires slow titration (6-8 weeks). Monitor for drug interactions with valproate and enzyme inducers.

Levetiracetam (Keppra): Minimal drug interactions, renal dosing required. Monitor for behavioral adverse effects. Widely available generic.

Lacosamide (Vimpat): Schedule V; approved adjunctive therapy for partial onset seizures. Monitor for cardiac conduction effects (PR prolongation).

Oxcarbazepine (Trileptal): Approved for adjunctive and monotherapy. Monitor sodium levels; be aware of oral contraceptive interaction.

Any transition away from tiagabine should include gradual tapering of tiagabine while cross-titrating the new AED to minimize seizure risk.

A Resource for Your Patients

For patients who are struggling to locate tiagabine at their local pharmacy, medfinder for providers can help your patients quickly identify pharmacies in their area that have tiagabine in stock. This reduces unnecessary emergency contacts and prescription-hunting anxiety for epilepsy patients who cannot safely miss doses.